NASDAQ:XOMAP XOMA (XOMAP) Stock Price, News & Analysis $25.72 -0.08 (-0.29%) Closing price 08/7/2025 03:43 PM EasternExtended Trading$25.74 +0.01 (+0.06%) As of 08/7/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About XOMA Stock (NASDAQ:XOMAP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XOMA alerts:Sign Up Key Stats Today's Range$25.56▼$25.5650-Day Range$25.44▼$26.0752-Week Range$24.96▼$26.51Volume140 shsAverage Volume1,580 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.40%Price TargetN/AConsensus RatingN/A Company Overview XOMA Corporation (NASDAQ:XOMAP) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and delivering therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. The company leverages its proprietary protein engineering and antibody discovery platforms to create novel biologic candidates designed to modulate key immune pathways. XOMA’s research focuses on targets implicated in conditions such as systemic lupus erythematosus, rheumatoid arthritis and other chronic inflammatory disorders. XOMA’s pipeline includes multiple antibody candidates at various stages of development, ranging from lead optimization to early clinical trials. The company employs structure‐guided design and high‐throughput screening to enhance the specificity and potency of its product candidates. XOMA also pursues strategic partnerships to co‐develop assets and expand its reach into new therapeutic areas, collaborating with academic institutions and industry leaders to accelerate progress from preclinical discovery to human studies. Founded in 1981 and headquartered in Berkeley, California, XOMA has driven innovation in protein therapeutics for more than three decades. The company operates research facilities in the San Francisco Bay Area and maintains relationships with contract development and manufacturing organizations worldwide. Under the leadership of President and Chief Executive Officer Paul Rubin, XOMA continues to build on its legacy of antibody discovery, with a focus on bringing first‐in‐class and best‐in‐class therapies to patients in need of novel treatments for immune‐mediated diseases.AI Generated. May Contain Errors. Read More Receive XOMAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMAP Stock News HeadlinesXOMA Co. (NASDAQ:XOMAP) Short Interest Up 1,400.0% in JulyAugust 3, 2025 | americanbankingnews.comXOMA-Backed XenoTherapeutics to Acquire Essa PharmaJuly 14, 2025 | marketwatch.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)XOMA To Acquire Turnstone Biologics For $0.34/Shr Plus Contingent Value Right - NasdaqJune 29, 2025 | nasdaq.comResults: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 16, 2025 | finance.yahoo.comBenchmark Initiates Coverage of XOMA Royalty (XOMA) with Buy RecommendationApril 17, 2025 | msn.comTrimble, Xoma announce new collaborationMarch 11, 2025 | markets.businessinsider.comXoma royalty corp sees sale of $16.98 million in stock by investorsJanuary 28, 2025 | msn.comSee More Headlines XOMAP Stock Analysis - Frequently Asked Questions How have XOMAP shares performed this year? XOMA's stock was trading at $25.88 at the beginning of 2025. Since then, XOMAP stock has decreased by 0.6% and is now trading at $25.7250. How do I buy shares of XOMA? Shares of XOMAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 7/15 Dividend7/03/2025Ex-Dividend for 7/15 Dividend7/03/2025Dividend Payable7/15/2025Today8/07/2025Next Earnings (Estimated)8/11/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XOMAP CIK791908 Webwww.xoma.com Phone510-204-7200FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$13.05 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:XOMAP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.